What labs and imaging studies should be ordered for a suspected insulinoma?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: June 12, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

For suspected insulinoma, initial laboratory evaluation should include fasting plasma glucose, insulin, C-peptide, and proinsulin levels during a supervised 72-hour fast, which is the gold standard diagnostic test, as recommended by 1 and 1. To diagnose insulinoma, the following labs should be ordered:

  • Fasting plasma glucose
  • Insulin
  • C-peptide
  • Proinsulin These tests should be performed during a supervised 72-hour fast, with blood samples drawn every 4-6 hours and when symptoms occur, and the fast terminated when hypoglycemia (glucose <45 mg/dL) develops 1. Additional tests should include:
  • Measurement of beta-hydroxybutyrate (low in insulinoma)
  • Screening for sulfonylurea use to exclude factitious hypoglycemia Elevated insulin (≥3 μU/mL), C-peptide (≥0.6 ng/mL), and proinsulin levels in the presence of hypoglycemia strongly suggest insulinoma 1. Once biochemical diagnosis is established, localization studies should include:
  • Contrast-enhanced CT or MRI of the abdomen as first-line imaging
  • Endoscopic ultrasound, which has high sensitivity for pancreatic lesions and can be used if initial imaging is negative 1
  • Selective arterial calcium stimulation testing with hepatic venous sampling may help regionalize the tumor in difficult cases 1
  • Somatostatin receptor scintigraphy (Octreoscan) or Gallium-68 DOTATATE PET/CT may be useful for detecting metastatic disease, but should be used with caution in patients with insulinoma, as they can worsen hypoglycemia 1.

From the Research

Laboratory Tests for Insulinoma

To diagnose an insulinoma, several laboratory tests can be ordered, including:

  • Fasting glucose levels to demonstrate hypoglycemia
  • Insulin levels to assess for inappropriate insulin secretion
  • C-peptide levels to evaluate for elevated C-peptide, a marker of insulin secretion 2
  • Proinsulin levels to assess for elevated proinsulin, which is often elevated in insulinoma 3
  • Sulfonylurea screening to rule out factitious hypoglycemia

Imaging Studies for Insulinoma

Imaging studies that can be performed to localize an insulinoma include:

  • Computed Tomography (CT) scan to visualize the pancreas and detect any masses 4
  • Magnetic Resonance Imaging (MRI) to provide detailed images of the pancreas and detect any tumors
  • Endoscopic Ultrasound (EUS) to visualize the pancreas and detect any small tumors
  • Somatostatin Receptor Scintigraphy (SRS) to detect any tumors that express somatostatin receptors

Diagnostic Tests for Insulinoma

Diagnostic tests that can be used to diagnose an insulinoma include:

  • 48-hour fast test to demonstrate Whipple's triad and assess for inappropriate insulin secretion 3
  • 72-hour fast test to demonstrate Whipple's triad and assess for inappropriate insulin secretion 5
  • 5-hour oral glucose tolerance test (OGTT) to assess for abnormal insulin and C-peptide secretion 6
  • Glucagon stimulation test to assess for exaggerated insulin response and diagnose insulinoma 4

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

C-peptide during the prolonged fast in insulinoma.

The Journal of clinical endocrinology and metabolism, 1993

Research

Forty-eight-hour fast: the diagnostic test for insulinoma.

The Journal of clinical endocrinology and metabolism, 2000

Research

Insulinoma in a patient with normal results from prolonged fast and glucagon-induced hypoglycemia.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2010

Research

ANTHROPOMETRIC FEATURES ARE NOT PREDICTIVE OF 72-HOUR FAST DURATION IN INSULINOMAS.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2017

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.